1. India Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Biocon Limited

Biocon Limited

BIOCON.NS
Biocon LimitedIN flagNational Stock Exchange of India
417.75
INR
+14.20
- -
571.22BMarket Cap
Biocon Limited
BIOCON.NS
(National Stock Exchange of India)

Recent

price

417.75

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
15.25
17.43
20.65
24.22
25.49
27.66
32.65
33.72
45.47
51.89
59.03
67.37
91.64
118.75
125.67
122.72
124.36
Revenue per Share
2.9
2.88
4.33
3.51
4.14
4.67
5.2
3.16
7.65
6.32
6.24
5.44
3.88
8.55
8.46
2.82
2.85
Basic EPS, GAAP
4.76
2.26
0.94
-2.02
-5.88
-3.68
-1.04
-2.16
-2.85
-4.67
-4.94
-6.28
1.06
8.55
14.34
0.6
- -
Free Cash Flow per Basic Share
0.6
0.77
0.85
1.49
1
1.87
- -
0.67
0.67
0.59
- -
- -
0.6
1.7
0.69
0.66
- -
Dividend per Share
12.36
14.01
16.62
18.82
20.88
27.74
33.98
38.39
46.55
55.01
57.58
62.36
139.86
152.27
163.3
5.93
5.99
Book Value per Share
15.65
18.31
22.39
25.18
26.28
34.41
41.05
42.84
49.66
53.32
61.56
68.47
-34.98
-11.58
5.47
57.13
57.73
Tangible Book Value per Share
1,173
1,175
1,175
1,177
1,200
1,178
1,178
1,180
1,183
1,184
1,187
1,191
1,193
1,195
1,198
1,367
1,353
Basic Weighted Avg Shares
17,898
20,490
24,263
28,513
30,592
32,580
38,458
39,781
53,811
61,448
70,074
80,248
109,341
141,958
150,522
167,799
168,299
Sales/Revenue/Turnover
20.75
16.77
16.31
17.83
16.17
16.25
18.34
11.17
17.65
17.13
13.64
14.79
14.88
10.11
9.83
8.93
8.8
Operating Margin (%)
1,567
1,758
1,793
2,036
2,210
2,487
2,772
3,851
4,478
5,522
7,151
8,142
11,131
15,688
16,870
19,567
19,567
Depreciation Expense
3,399
3,384
5,089
4,138
4,974
5,504
6,121
3,724
9,053
7,482
7,405
6,484
4,627
10,225
10,133
3,856
3,856
Net Income, GAAP
14.71
13.78
15.98
19.88
15.33
18.93
19.02
25.72
17.47
25.94
20.75
21.51
28.32
14.91
24.23
17.66
17.66
Effective Tax Rate (%)
18.99
16.52
20.97
14.51
16.26
16.89
15.92
9.36
16.82
12.18
10.57
8.08
4.23
7.2
6.73
2.3
2.29
Profit Margin (%)
7,466
9,839
12,501
12,592
8,776
23,052
23,694
20,073
18,500
13,170
33,903
45,543
38,233
-1,796
19,524
31,106
31,106
Working Capital
74
244
1,316
5,868
7,671
20,724
21,082
17,898
15,407
13,053
30,757
42,200
154,996
134,248
129,445
112,833
112,833
LT Debt
20,705
22,762
27,599
31,090
33,743
42,996
52,138
56,485
67,069
73,831
85,076
94,700
224,888
252,748
277,125
366,215
366,215
Total Equity
13.51
12.14
12.07
11.68
9.84
7.52
7.89
4.23
9.1
8.01
6.48
6.66
4.18
2.95
2.54
2.5
2.47
Return on Invested Capital (%)
16.97
18.84
24.63
14.75
13.63
10.42
8.78
4.88
10.96
7.3
6.16
4.48
2.2
3.98
3.04
3.88
3.88
Return on Capital (%)
21.19
21.86
28.28
19.85
21.07
19.07
16.84
8.73
18.04
12.45
11.09
9.09
3.84
5.86
5.37
3.79
3.79
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
ST Debt
54,074
- -
41,508
LT Borrowings
105,700
- -
107,463
LT Finance Leases
5,581
- -
5,370
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,335
- -
1,620
Market Capitalization
415,970
493,917
488,401

Working Capital

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
Total Current Assets
187,811
- -
171,798
Cash, Cash Equivalents & STI
64,692
- -
41,984
Accounts Receivable, Net
55,192
- -
59,868
Inventories
57,768
- -
60,857
Total Current Liabilities
162,542
- -
140,692
Payables & Accruals
- -
- -
- -
ST Debt
54,074
- -
41,508
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
27.66%
40.59%
32.15%
Free Cash Flow
73.28%
118.71%
-95.21%
Net Income, GAAP
11.38%
3.41%
-61.95%
Sales/Revenue/Turnover
18.31%
19.62%
11.48%
Total Cash Common Dividend
- -
- -
9.53%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
33,907
33,926
35,487
38,638
141,958
2025
33,761
35,450
38,214
43,581
150,522
2026
39,101
42,625
41,730
44,843
167,799

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.85
1.05
5.52
- -
8.55
2025
5.51
-0.13
0.21
2.88
8.46
2026
0.26
0.66
1.08
0.79
2.82

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
1.7
2025
- -
- -
- -
- -
0.69
2026
- -
- -
- -
- -
0.66
Similar Companies
Avacta Group Plc (AVCT.L)
Catalyst Pharmaceuticals, Inc. (CPRX)
Sesen Bio, Inc. (SESN)
Palisade Bio, Inc. (PALI)
Intellipharmaceutics International Inc. (IPCI.TO)
Alnylam Pharmaceuticals, Inc. (DUL.DE)
Business
Biocon Limited, India's largest biopharmaceutical company headquartered in Bengaluru and founded in 1978 by Kiran Mazumdar-Shaw, develops, manufactures and markets a broad portfolio of generics, biosimilars, novel biologics and branded formulations; its core offerings encompass active pharmaceutical ingredients including cardiovascular, anti-diabetics, immunosuppressants, statins, anti-cancer, anti-fungal and multiple sclerosis therapies; biosimilar insulins such as INSUGEN and BASALOG, monoclonal antibodies like BIOMAb EGFR, CANMAb, ALZUMAb and KRABEVA, alongside formulations in metabolics, oncology, immunotherapy and nephrology including Evertor, TACROGRAF and BLISTO; and contract research services through its listed subsidiary Syngene International. The company operates manufacturing facilities in Bengaluru and Malaysia, with products sold in over 120 countries encompassing the United States, Europe, Japan, Australia and emerging markets including India. Biocon Biologics, its biosimilars subsidiary in which it holds a 90.2% stake, drives much of its advanced biologics pipeline. In recent developments, Biocon Biologics expanded its partnership with Civica in 2025 to launch private-label insulin glargine in the United States; the company raised ₹4,500 crore through a qualified institutional placement in June 2025 to bolster its Biocon Biologics stake and facilitate private equity exits; it explores a potential merger of Biocon Biologics valued at $4.5 billion advised by Morgan Stanley to streamline operations and enhance shareholder value; Biocon announced partnerships such as with Tabuk Pharmaceuticals for commercialization and the acquisition of Eywa Pharma's manufacturing facility as of December 2025; and earlier integrated Viatris' global biosimilars business acquired in 2022 for $3.34 billion.

Company News

APIChatGPT

  • prnewswire.com

    Shreehas Tambe nombrado CEO y Director General de Biocon Limited con efectos a partir del 1 de abril de 2026

  • prnewswire.com

    Shreehas Tambe übernimmt zum 1. April 2026 die Rolle des Executive Officer und Managing Director bei Biocon Limited